Update on phase III KEYLYNK-006 trial evaluating Keytruda (pembrolizumab) + maintenance Lynparza (olaparib) for certain patients with metastatic non-squamous non-small cell lung cancer. Merck Inc., + AstraZeneca
Merck Inc., known as MSD outside of the United States and Canada, announced that the Phase III KEYLYNK-006 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, in combination with maintenance Lynparza, a PARP inhibitor, did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) for the first-line treatment of certain patients with metastatic nonsquamous non-small cell lung cancer (NSCLC).